p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 424-431

  Sáez, Rosana ^a   Molina, Miguel A ^c   Ramsey, Elizabeth E ^d   Rojo, Federico ^c   Keenan, Edward J ^d   Albanell, Joan ^c   Lluch, Ana ^b   Garcia Conde, Javier ^b   Baselga, José ^c   Clinton, Gail M ^d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; P95HER 2 PROTEIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RISK FACTOR; SPAIN; STATISTICAL ANALYSIS; UNITED STATES; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 31544465529     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1807     Document Type: Article

References (43)

1. Spector NL, Xia W, Burris H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
3. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003;194:13-9.
4. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931-41.
5. Monnier L, Milano G, Penault-Llorca F, Merlin JL. Targeting of membrane receptor tyrosine kinases: is there resistance in the HER? Bull Cancer 2004;91:685-94.
6. Friedman LM, Rinon A, Schechter B, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 2005;102:1915-20.
7. Henderson IC, Patek AJ. The relationship between prognostic and predictive factor in the management of breast cancer. Breast Cancer Res Treat 1998;52:261-8.
8. Mirza AN, Mirza NQ, Vlastos G, Singletary E. Prognostic factors in node-negative breast cancer. Ann Surg 2002;235:20-6.
9. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells 1998;16:413-28.
10. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A 1999;96:10869-74.
11. Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton GM. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 2003;22:8178-86.
12. Lin YL, Clinton GM. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 1991;6:639-43.
13. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi M. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993;8:2917-23.
14. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-20.
15. Brandt-Rauf PW. The c-erb transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res 1995;333:203-8.
16. Molina R, Zanon JJ, Filella X, et al. Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA. Br J Cancer 1996;4:1126-31.
17. Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 1997;73:875-9.
18. Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragment in serum correlates with disease state and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994;70:739-42.
19. Fehm T, Maimonis P, Katalinic A, Jager WH. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998;55:33-8.
20. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormonal therapy of breast cancer. J Clin Oncol 1995;13:1129-235.
21. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1996;15:18-25.
22. Colomer R, Montero S, Lluch A, et al. Circulating HER-2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6:2356-62.
23. Harris LN, Track B, Berris M, Esteva-Lorenzo F, Paik S. The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients [Meeting abstract]. Proc Am Soc Clin Oncol 1996;15:A96.
24. 2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998;15:5123-9.
25. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin®), a humanized anti-HER-2 receptor monoclonal antibody, inhibits basal and activated HER-2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;15:4744-9.
26. DiFiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-82.
27. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988;8:5570-4.
28. Staverosky JA, Muldoon LL, Guo S, Evans AJ, Neuwelt EA, Clinton GM. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma. Clin Cancer Res 2005;11:335-40.
29. Penuel E, Akita RW, Sliwkowski MX. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem 2002;277:28468-73.
30. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001;28:4-11.
31. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-53.
32. 2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002;8:347-53.
33. Simon R, Nocito A, Hubsher T, et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-6.
34. Lin YJ, Li S, Clinton GM. Insulin and epidermal growth factor stimulate phosphorylation of p185HER-2/neu in the breast carcinoma line BT474. Mol Cell Endocrinol 1990;69:111-9.
35. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
36. Xing W-R, Gilchrist KW, Harris CP, et al. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996;39:203-12.
37. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
38. Bennasroune A, Gardin A, Aunis D, Cremel G, Hurbert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 2004;50:23-38.
39. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002;8:17-23.
40. Bache KG, Slagsvold T, Stenmark H. Defective downregulation of receptor tyrosine kinases in cancer. EMBO J 2004;21:2707-212.
41. Stearns ME, Wang M, Hu Y, Kim G, Garcia FU. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. Lab Invest 2004;84:785-95.
42. Bassi DE, Mahloogi H, Lopez de Cicco R, Klein-Szanto A. Increased furin activity enhances the malignant phenotype of human head and neck cancer. Am J Pathol 2003;192:439-47.
43. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER-2 ectodomain is a pervanadate activable process that is inhibited by the tissue inhibitor of metalloproteases TIMP-1 in breast cancer cells. Cancer Res 1999;59:1196-201.